AU2013245027B2 - Use of CCR3-inhibitors - Google Patents

Use of CCR3-inhibitors Download PDF

Info

Publication number
AU2013245027B2
AU2013245027B2 AU2013245027A AU2013245027A AU2013245027B2 AU 2013245027 B2 AU2013245027 B2 AU 2013245027B2 AU 2013245027 A AU2013245027 A AU 2013245027A AU 2013245027 A AU2013245027 A AU 2013245027A AU 2013245027 B2 AU2013245027 B2 AU 2013245027B2
Authority
AU
Australia
Prior art keywords
eosinophilic
alkyl
disease
formula
chloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013245027A
Other languages
English (en)
Other versions
AU2013245027A1 (en
Inventor
Thierry Bouyssou
Rolf Goeggel
Michael Chadham Nivens
Peter Seither
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkahest Inc
Original Assignee
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48040249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013245027(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkahest Inc filed Critical Alkahest Inc
Publication of AU2013245027A1 publication Critical patent/AU2013245027A1/en
Assigned to ALKAHEST, INC. reassignment ALKAHEST, INC. Request for Assignment Assignors: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Application granted granted Critical
Publication of AU2013245027B2 publication Critical patent/AU2013245027B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Structure Of Transmissions (AREA)
AU2013245027A 2012-04-03 2013-04-02 Use of CCR3-inhibitors Active AU2013245027B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12162937.2 2012-04-03
EP12162937 2012-04-03
PCT/EP2013/056864 WO2013149986A1 (en) 2012-04-03 2013-04-02 Use of ccr3-inhibitors

Publications (2)

Publication Number Publication Date
AU2013245027A1 AU2013245027A1 (en) 2014-09-11
AU2013245027B2 true AU2013245027B2 (en) 2017-10-12

Family

ID=48040249

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013245027A Active AU2013245027B2 (en) 2012-04-03 2013-04-02 Use of CCR3-inhibitors

Country Status (28)

Country Link
US (5) US20130261153A1 (OSRAM)
EP (3) EP2833884B1 (OSRAM)
JP (2) JP2015512432A (OSRAM)
KR (5) KR20210063481A (OSRAM)
CN (2) CN104220073A (OSRAM)
AU (1) AU2013245027B2 (OSRAM)
BR (1) BR112014023795B1 (OSRAM)
CA (1) CA2869269C (OSRAM)
CL (1) CL2014002523A1 (OSRAM)
CY (1) CY1123222T1 (OSRAM)
DK (1) DK2833884T3 (OSRAM)
EA (1) EA032263B1 (OSRAM)
ES (2) ES2811554T3 (OSRAM)
HR (1) HRP20201165T1 (OSRAM)
HU (1) HUE051648T2 (OSRAM)
IL (1) IL234262A (OSRAM)
IN (1) IN2014DN06989A (OSRAM)
LT (1) LT2833884T (OSRAM)
MX (1) MX2014011786A (OSRAM)
NZ (1) NZ628882A (OSRAM)
PH (1) PH12014502239A1 (OSRAM)
PL (1) PL2833884T3 (OSRAM)
PT (1) PT2833884T (OSRAM)
RS (1) RS60665B1 (OSRAM)
SI (1) SI2833884T1 (OSRAM)
SM (1) SMT202000499T1 (OSRAM)
WO (1) WO2013149986A1 (OSRAM)
ZA (1) ZA201406082B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
CN109310486B (zh) 2016-11-24 2021-07-02 雾岛精工株式会社 齿列矫正器和齿列矫正器的安装方法
JP2020513005A (ja) 2017-04-05 2020-04-30 アルカヘスト，インコーポレイテッド Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法及び組成物
ES2950453T3 (es) * 2017-04-05 2023-10-10 Alkahest Inc Compuestos y composiciones farmacéuticas para su uso en el tratamiento de enfermedades asociadas a la retina utilizando inhibidores de la CCR3
SG11202002437VA (en) * 2017-10-13 2020-04-29 Alkahest Inc Methods and compositions for treating pruritus, xerosis, and associated disease using ccr3-inhibitors
CN112469439A (zh) 2018-05-15 2021-03-09 万能溶剂有限公司 用白三烯a4水解酶调节剂治疗衰老相关性疾病
JP7528065B2 (ja) * 2018-09-26 2024-08-05 アルカヘスト，インコーポレイテッド Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法および組成物
WO2021252647A1 (en) * 2020-06-11 2021-12-16 Alkahest Inc. Methods of improving retina-associated disease outcome using ccr3-inhibitors
AU2022376563A1 (en) 2021-11-01 2023-12-07 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090123375A1 (en) * 2007-10-09 2009-05-14 University Of Kentucky Research Foundation CCR3 Inhibition for Ocular Angiogenesis and Macular Degeneration
WO2010069979A1 (en) * 2008-12-16 2010-06-24 Nycomed Gmbh Pyran derivatives as ccr3 modulators
WO2010115836A1 (en) * 2009-04-08 2010-10-14 Boehringer Ingelheim International Gmbh Substituted piperidines as ccr3 antagonists
WO2010138591A1 (en) * 2009-05-26 2010-12-02 University Of Kentucky Research Foundation Ccr3 and its ligands are therapeutic and diagnostic targets for neovascular age-related macular degeneration
WO2012045803A1 (en) * 2010-10-07 2012-04-12 Boehringer Ingelheim International Gmbh Co-crystals and salts of ccr3-inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339087B1 (en) * 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
ATE414151T1 (de) * 2000-03-03 2008-11-15 Cambridge Antibody Tech Antikörper gegen eotaxin und deren verwendung
US20020151064A1 (en) * 2001-02-07 2002-10-17 Children's Hospital Medical Center Regulation of CCR3 expression
US8030003B2 (en) * 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
WO2020115836A1 (ja) * 2018-12-05 2020-06-11 東浜工業株式会社 ブロワー装置

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090123375A1 (en) * 2007-10-09 2009-05-14 University Of Kentucky Research Foundation CCR3 Inhibition for Ocular Angiogenesis and Macular Degeneration
WO2010069979A1 (en) * 2008-12-16 2010-06-24 Nycomed Gmbh Pyran derivatives as ccr3 modulators
WO2010115836A1 (en) * 2009-04-08 2010-10-14 Boehringer Ingelheim International Gmbh Substituted piperidines as ccr3 antagonists
WO2010138591A1 (en) * 2009-05-26 2010-12-02 University Of Kentucky Research Foundation Ccr3 and its ligands are therapeutic and diagnostic targets for neovascular age-related macular degeneration
WO2012045803A1 (en) * 2010-10-07 2012-04-12 Boehringer Ingelheim International Gmbh Co-crystals and salts of ccr3-inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAKEDA A. et al. "CCR3 is a target for age-related macular degeneration diagnosis and therapy", Nature, 2009, Vol. 460, No. 7252, pages 225-230 *

Also Published As

Publication number Publication date
BR112014023795B1 (pt) 2021-09-08
EP4389217A2 (en) 2024-06-26
CL2014002523A1 (es) 2015-01-23
EP4389217A3 (en) 2024-08-28
US20200375971A1 (en) 2020-12-03
LT2833884T (lt) 2020-09-10
JP2018080183A (ja) 2018-05-24
HRP20201165T1 (hr) 2020-12-11
CY1123222T1 (el) 2021-10-29
HUE051648T2 (hu) 2021-03-29
IN2014DN06989A (OSRAM) 2015-04-10
EP2833884B1 (en) 2020-05-20
EP3763369A1 (en) 2021-01-13
PL2833884T3 (pl) 2020-11-02
DK2833884T3 (da) 2020-08-10
ES2987267T3 (es) 2024-11-14
RS60665B1 (sr) 2020-09-30
IL234262A (en) 2017-10-31
BR112014023795A2 (OSRAM) 2017-06-20
CA2869269C (en) 2020-06-30
KR20220132012A (ko) 2022-09-29
PH12014502239A1 (en) 2014-12-15
EA032263B1 (ru) 2019-05-31
WO2013149986A1 (en) 2013-10-10
PT2833884T (pt) 2020-08-26
US20160081998A1 (en) 2016-03-24
CA2869269A1 (en) 2013-10-10
EA201401083A1 (ru) 2015-03-31
NZ628882A (en) 2016-05-27
JP2015512432A (ja) 2015-04-27
MX2014011786A (es) 2014-12-05
KR20140144200A (ko) 2014-12-18
EP2833884A1 (en) 2015-02-11
ZA201406082B (en) 2019-01-30
KR20200044988A (ko) 2020-04-29
US20130261153A1 (en) 2013-10-03
AU2013245027A1 (en) 2014-09-11
EP3763369B1 (en) 2024-02-28
BR112014023795A8 (pt) 2017-10-10
US20170319567A1 (en) 2017-11-09
CN110384699A (zh) 2019-10-29
CN104220073A (zh) 2014-12-17
ES2811554T3 (es) 2021-03-12
KR20210063481A (ko) 2021-06-01
SI2833884T1 (sl) 2020-10-30
SMT202000499T1 (it) 2020-11-10
KR20250133980A (ko) 2025-09-09
US20150099783A1 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
AU2013245027B2 (en) Use of CCR3-inhibitors
AU2013245028B2 (en) Pharmaceutical formulations comprising ccr3 antagonists
HK40015701A (en) Use of ccr3-inhibitors
WO2004034973A2 (en) Method of treating snoring and other obstructive breathing disorders
JP2007518768A (ja) 有機化合物の組み合わせ物
WO2016006621A1 (ja) Ｐｇｄ２拮抗剤を含有するアレルギー性疾患に伴う症状の治療用医薬
JP2010111667A (ja) フェキソフェナジン又はエバスチンを含有する鎮咳及び／又は去痰のための医薬組成物
US20080139615A1 (en) Combination of a hypnotic agent and r (+)-alpha-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and therapeutic application thereof
TW200906406A (en) Use of a compound that is a neurokinin A NK2 receptor antagonist for the preparation of medicaments for use in the prevention and treatment of sexual dysfunctions

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ALKAHEST, INC.

Free format text: FORMER APPLICANT(S): BOEHRINGER INGELHEIM INTERNATIONAL GMBH

FGA Letters patent sealed or granted (standard patent)